BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enozertinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enozertinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06816992-2662@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Enozertinib: Phase 1 readout est. (NCT06816992)
DESCRIPTION:Enozertinib\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: ORI
 C-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR E
 xon20 Insertion Mutant NSCLC\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/enozertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06816992
URL:https://assetmemo.bio/drug/enozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05315700-2662@assetmemo.bio
DTSTAMP:20261121T005638Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Enozertinib: Phase 1/2 readout est. (NCT05315700)
DESCRIPTION:Enozertinib\, phase 1/2.\nStudy: Study of ORIC-114 in Patients 
 With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/enozertinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05315700
URL:https://assetmemo.bio/drug/enozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
